BACKGROUND AND PURPOSE: High b-value DWI has been expected to have an additional diagnostic role and demonstrated some promising results in head and neck cancer. The aim of this study was to evaluate the diagnostic performance of DWI at a high b-value (b=2000 s/mm(2)) compared with a standard b-value (b=1000 s/mm(2)) and the ratio of ADC values of high and standard b-values for their ability to differentiate between recurrent tumor and posttreatment changes after the treatment of head and neck squamous cell carcinoma. MATERIALS AND METHODS: A total of 33 patients diagnosed with head and neck squamous cell carcinoma were enrolled in the present study; all had contrast-enhancing lesions on follow-up MR imaging. All patients underwent single-shot echo-planar DWI at b=1000 s/mm(2) and b=2000 s/mm(2), and corresponding ADC maps were generated (ADC1000 and ADC2000, respectively). The mean ADC1000, ADC2000, and ADCratio (ADCratio = ADC2000/ADC1000 × 100) values were evaluated within a manually placed ROI with contrast-enhanced T1-weighted images as references. For the statistical analysis, we performed a Student t test and multivariate logistic regression. RESULTS: The mean ADC1000 in recurrent tumor was significantly lower than that in posttreatment changes (P < .001), whereas the mean ADC2000 resulted in no significant difference (P = .365). The mean ADCratio was significantly higher in recurrent tumor than that in posttreatment changes (73.5 ± 7.2% vs 56.9 ± 8.8%, respectively; P < .001). Multivariate logistic regression analysis revealed that the ADCratio was the only independently differentiating variable (P = .024). The sensitivity, specificity, and accuracy of ADCratio were 95.0%, 69.2%, and 84.8%, respectively, by use of the optimal cutoff value of 62.6%. CONCLUSIONS: We suggest that the ADCratio calculated from the ADC1000 and ADC2000 is a promising value for the differentiation of recurrent tumor and posttreatment changes in head and neck squamous cell carcinoma.
BACKGROUND AND PURPOSE: High b-value DWI has been expected to have an additional diagnostic role and demonstrated some promising results in head and neck cancer. The aim of this study was to evaluate the diagnostic performance of DWI at a high b-value (b=2000 s/mm(2)) compared with a standard b-value (b=1000 s/mm(2)) and the ratio of ADC values of high and standard b-values for their ability to differentiate between recurrent tumor and posttreatment changes after the treatment of head and neck squamous cell carcinoma. MATERIALS AND METHODS: A total of 33 patients diagnosed with head and neck squamous cell carcinoma were enrolled in the present study; all had contrast-enhancing lesions on follow-up MR imaging. All patients underwent single-shot echo-planar DWI at b=1000 s/mm(2) and b=2000 s/mm(2), and corresponding ADC maps were generated (ADC1000 and ADC2000, respectively). The mean ADC1000, ADC2000, and ADCratio (ADCratio = ADC2000/ADC1000 × 100) values were evaluated within a manually placed ROI with contrast-enhanced T1-weighted images as references. For the statistical analysis, we performed a Student t test and multivariate logistic regression. RESULTS: The mean ADC1000 in recurrent tumor was significantly lower than that in posttreatment changes (P < .001), whereas the mean ADC2000 resulted in no significant difference (P = .365). The mean ADCratio was significantly higher in recurrent tumor than that in posttreatment changes (73.5 ± 7.2% vs 56.9 ± 8.8%, respectively; P < .001). Multivariate logistic regression analysis revealed that the ADCratio was the only independently differentiating variable (P = .024). The sensitivity, specificity, and accuracy of ADCratio were 95.0%, 69.2%, and 84.8%, respectively, by use of the optimal cutoff value of 62.6%. CONCLUSIONS: We suggest that the ADCratio calculated from the ADC1000 and ADC2000 is a promising value for the differentiation of recurrent tumor and posttreatment changes in head and neck squamous cell carcinoma.
Authors: Francisco Purroy; Robert Begue; Alejandro Quílez; Jordi Sanahuja; Maria Isabel Gil Journal: J Neuroimaging Date: 2012-02-06 Impact factor: 2.486
Authors: Vincent Vandecaveye; Frederik De Keyzer; Sandra Nuyts; Karen Deraedt; Piet Dirix; Pascal Hamaekers; Vincent Vander Poorten; Pierre Delaere; Robert Hermans Journal: Int J Radiat Oncol Biol Phys Date: 2006-12-04 Impact factor: 7.038
Authors: A A K Abdel Razek; A Y Kandeel; N Soliman; H M El-shenshawy; Y Kamel; N Nada; A Denewar Journal: AJNR Am J Neuroradiol Date: 2007 Jun-Jul Impact factor: 3.825
Authors: Marcelo A Queiroz; Martin Hüllner; Felix Kuhn; Gerhardt Huber; Christian Meerwein; Spyros Kollias; Gustav von Schulthess; Patrick Veit-Haibach Journal: Eur J Nucl Med Mol Imaging Date: 2014-08-05 Impact factor: 9.236
Authors: A Jajodia; G Mandal; V Yadav; J Khoda; J Goyal; S Pasricha; S Puri; A Dewan Journal: AJNR Am J Neuroradiol Date: 2022-06-23 Impact factor: 4.966